The pharmaceutical industry is experiencing an unprecedented wave of patent litigation as major drug manufacturers face challenges from generic competitors seeking to bring lower-cost alternatives to market. Court filings from early 2025 reveal over 100 new Abbreviated New Drug Application (ANDA) cases spanning critical therapeutic areas and involving some of the industry's most valuable medications.
Oncology Drugs Under Siege
AstraZeneca faces multiple patent challenges for Lynparza (olaparib tablets), with four separate cases filed against generic manufacturers including Natco Pharma, Sandoz, Cipla, and Zydus Pharmaceuticals. The litigation centers on patent 12,178,816, highlighting the significant commercial interest in this PARP inhibitor used to treat various cancers.
Exelixis is defending patents for both Cometriq and Cabometyx (cabozantinib formulations) against Azurity Pharmaceuticals and MSN Labs respectively. The cases involve patent 12,128,039, underscoring the competitive pressure on these kidney and liver cancer treatments.
Celgene Corporation, now part of Bristol Myers Squibb, is protecting Pomalyst (pomalidomide capsules) against Cipla, with litigation involving multiple patents including 8,828,427, 9,993,467, and 10,555,939. This multiple myeloma treatment represents a significant revenue stream facing generic competition.
Cardiovascular and Metabolic Therapies
Novartis is defending Entresto (sacubitril/valsartan tablets) against MSN Labs in a case involving patent 8,101,659. This heart failure medication has become a cornerstone therapy, making generic competition particularly significant for both patients and the company's revenue.
Novo Nordisk filed suit against Mylan Pharmaceuticals over Wegovy (semaglutide injection), involving patent 12,214,017. The litigation highlights the intense competition in the rapidly growing GLP-1 receptor agonist market for diabetes and weight management.
Bayer is protecting Xarelto (rivaroxaban tablets) against Lupin with patent 10,828,310 at stake. This anticoagulant represents one of the most prescribed blood thinners globally, making generic entry highly anticipated.
Neurological and Psychiatric Medications
Multiple companies are defending treatments for neurological conditions. Harmony Biosciences is protecting Wakix (pitolisant HCl tablets) against Lupin, involving patents 8,486,947 and 8,207,197. This narcolepsy treatment represents a specialized market with limited alternatives.
Intra-Cellular Therapies filed against Zydus Pharmaceuticals over Caplyta (lumateperone capsules), with patents 9,956,227, 10,960,009, 11,026,951, and RE48,839 involved. This schizophrenia and bipolar depression treatment faces generic competition despite its relatively recent market entry.
Acadia Pharmaceuticals is defending Nuplazid (pimavanserin tablets) against Zydus Lifesciences, involving multiple patents including 7,601,740, 7,659,285, and 7,732,615. This Parkinson's disease psychosis treatment represents a unique therapeutic option in its indication.
Specialized Therapeutic Areas
The litigation extends to specialized treatments across various therapeutic areas. BioCryst Pharmaceuticals is protecting Orladeyo (berotralstat dihydrochloride capsules) against Annora Pharma, involving patents 10,662,160, 11,117,867, and 11,618,733. This hereditary angioedema treatment serves a rare disease population with limited therapeutic options.
Genentech filed against Zydus Lifesciences Global over Evrysdi (risdiplam solution), involving patent 12,122,789. This spinal muscular atrophy treatment represents a critical therapy for a devastating pediatric condition.
Patent Landscape and Market Implications
The surge in ANDA litigation reflects the natural patent cliff phenomenon, where blockbuster drugs lose exclusivity protection. The cases span multiple federal district courts, including Delaware, New Jersey, and others, indicating the strategic importance companies place on defending their intellectual property.
The Patent Trial and Appeal Board (PTAB) is also seeing increased activity, with inter partes review (IPR) and post-grant review (PGR) proceedings challenging patent validity. These proceedings offer alternative pathways for generic manufacturers to clear patent obstacles.
The litigation involves patents with various expiration dates and covers different aspects of drug development, from active pharmaceutical ingredients to formulation techniques and manufacturing processes. This comprehensive patent protection strategy reflects the significant investment pharmaceutical companies make in developing new therapies.
The outcome of these cases will significantly impact both brand-name manufacturers' revenue streams and patients' access to more affordable generic alternatives. The timing and success of generic entries can dramatically alter market dynamics, potentially saving healthcare systems billions of dollars while affecting companies' ability to fund future research and development.
